Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort Study
Cutis · 01.03.2026 · 3 (117)
DOI: 10.12788/cutis.1352 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cutis, erschienen am 01.03.2026. Verfasst von Zaryab Alam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zaryab Alam is from the College of Medicine, Texas A&M University, Bryan. Kevin T. Nguyen and Kritin K. Verma are from the School of Medicine, Texas ….
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Zaryab Alam is from the College of Medicine, Texas A&M University, Bryan. Kevin T. Nguyen and Kritin K. Verma are from the School of Medicine, Texas Tech University Health Sciences Center, Lubbock. Drs. Kunadia and Levi…
Zitieren
APA
Alam, Z., Nguyen, K. T., Verma, K. K., Kunadia, A., & Levin, J. I. (2026). Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort Study. Cutis, 3(117). https://doi.org/10.12788/cutis.1352
Vancouver
Alam Z, Nguyen KT, Verma KK, Kunadia A, Levin JI. Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort Study. Cutis. 2026;3(117). doi:10.12788/cutis.1352
BibTeX
@article{Alam2026,
author = {Alam, Zaryab and Nguyen, Kevin T and Verma, Kritin K and Kunadia, Anuj and Levin, Jarad I},
title = {Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort Study},
journal = {Cutis},
year = {2026},
volume = {3},
number = {117},
doi = {10.12788/cutis.1352}
}
EUVIMED